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Abstract
Background: As part of the immune defense during infec-
tion, an increase in enzyme activity of indoleamine 
2,3-dioxygenase (IDO) leads to a breakdown of tryptophan 
to kynurenine. In previous animal studies, therapeutic 
antagonism of IDO resulted in reduced sepsis mortality. We 
investigated the prognostic ability of tryptophan, serotonin, 
kynurenine and IDO (represented by the ratio of kynure-
nine/tryptophan) to predict adverse clinical  outcomes in 
patients with community-acquired  pneumonia (CAP).
Methods: We measured tryptophan, serotonin and 
kynurenine on admission plasma samples from CAP 
patients included in a previous multicenter trial by liquid 
chromatography coupled with tandem mass spectrometry 
(LC-MS/MS). We studied their association with inflam-
mation (C-reactive protein), infection (procalcitonin) and 
clinical outcome.
Results: Mortality in the 268 included patients was 45% 
within 6 years of follow-up. IDO and kynurenine showed a 
strong positive correlation with markers of infection (pro-
calcitonin) and inflammation (C-reactive protein) as well 
as sepsis and CAP severity scores. Tryptophan showed 
similar, but negative correlations. In a multivariate regres-
sion analysis adjusted for age and comorbidities, higher 
IDO activity and lower tryptophan levels were strongly 
associated with short-term adverse outcome defined as 
death and/or ICU admission within 30 days with adjusted 
odds ratios of 9.1 [95% confidence interval (CI) 1.4–59.5, 
p = 0.021] and 0.11 (95% CI 0.02–0.70, p = 0.021). Multi-
variate analysis did not reveal significant associations for 
kynurenine and serotonin.
Conclusions: In hospitalized CAP patients, higher IDO 
activity and lower tryptophan levels independently pre-
dicted disease severity and short-term adverse outcome. 
Whether therapeutic modulation of IDO has positive 
effects on outcome needs further investigation.
Keywords: community-acquired pneumonia; indoleam-
ine 2,3-dioxygenase; kynurenine; long-term; mortality; 
prediction; serotonin; tryptophan.
Introduction
Tryptophan (TRP) is an essential amino acid and plays a 
key role in mammals as a precursor of physiological sub-
stances including serotonin 5-Hydroxytryptamine (5-HT) 
and melatonin [1]. Particularly TRP and its metabolites 
are thought to be altered during infections as part of the 
immune reaction [2, 3]. There are two metabolic path-
ways in the breakdown of TRP [4] (illustrated in Figure 
1). About 95% of TRP is metabolized via the kynurenine 
(KYN) pathway. The rate-limiting enzymes are tryptophan 
2,3-dioxygenase (TDO) localized in hepatic tissue and 
indoleamine 2,3-dioxygenase (IDO) in extrahepatic tissue. 
IDO is inducible by interferon-γ and is thus the rate lim-
iting enzyme in an infective condition [5, 6]. The seroto-
nin 5-HT pathway is catalyzed by tryptophan hydroxylase 
(TPH), whereas less than 5% of TRP is metabolized by this 
pathway [4].
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Initially, IDO was recognized as a potent antimicro-
bial effector molecule. Its antimicrobial effect was thought 
to exist through a breakdown of TRP as TRP is essential 
for the growth of microorganisms. However, recent studies 
have demonstrated its novel role as a strong inhibitor of 
T  cell proliferation [2]. Sepsis-induced elevation of 5-HT 
has recently been discovered in a mouse model where high 
levels of 5-HT facilitated endothelial hyperpermeability 
[3]. Microvascular dysfunction is believed to contribute to 
patient mortality in sepsis [7]. Therefore an intervention 
with a 5-HT transporter inhibitor was speculated to be a 
potential therapeutic option [3].
Community-acquired pneumonia (CAP) is currently 
the leading cause of death due to an infectious disease [8] 
and responsible for high costs, morbidity, and mortality 
worldwide [9, 10]. Serum activity of IDO predicted short-
term prognosis in a small cohort of 129 CAP patients [11]. 
However, this study did not measure serotonin. In a state 
of infection, the catabolism of TRP is activated [12]. Given 
these results from mostly animal studies, there is interest 
in a larger clinical study investigating how adaptations in 
the TRP/5-HT pathway interact with severity and outcome 
in patients with a well-defined infection. This will allow 
better understanding whether therapeutic interventions 
targeted at this pathway could bring benefits.
Herein, our aim was to investigate the association 
of metabolites of the TRP/5-HT pathway with severity 
and outcome in a well-characterized cohort of patients 
 hospitalized for CAP with a follow-up over more than six 
years.
Materials and methods
Study design
A total of 268 patients hospitalized for CAP and available blood 
specimens from a previous Swiss multicenter trial [13, 14] were 
95% TRP 5%
IDO
TDO
TPH
5-HTKYN
Figure 1: Tryptophan/serotonin pathway.
TRP, tryptophan; KYN, kynurenine; IDO, indoleamine 2,3-dioxy-
genase; TDO, tryptophan 2,3-dioxygenase; 5-HT, serotonin; TPH, 
tryptophan hydroxylase.
included in this analysis. The initial trial included 925 (68%) CAP 
patients in which all-cause mortality was 45% over a follow-up 
period of 6 years [15].
The initial trial was a randomized controlled, antibiotic stew-
ardship trial performed between October 2006 and March 2008 at six 
Swiss secondary and tertiary care centers and described elsewhere 
[13]. The primary goal of the study was to verify the efficacy and 
safety of using the procalcitonin (PCT) level to guide the initiation 
and duration of antibiotic therapy in patients with lower respiratory 
tract infections [13, 14]. Patients at least 18 years of age presenting 
from the community or a nursing home to the emergency department 
(ED) were included if they fulfilled at least one of the following crite-
ria: cough, dyspnea, pleural pain, sputum production or tachypnea 
and one infectious sign (core body temperature > 38 °C, shivering, 
white blood cell count > 10 or < 4 cells × 109 L‒ 1) or one finding during 
auscultation (rales or crepitation). In all patients with CAP at that 
time an infiltrate was radiologically confirmed. Patients with lan-
guage restriction or dementia that precluded from providing written 
informed consent, intravenous drug use, terminal condition or hos-
pital-acquired pneumonia were excluded. Participants were allowed 
to receive corticosteroids or short-term antibiotic pretreatment but 
were excluded if they suffered from severe immunosuppression or 
received long-term antibiotic pretreatment at ED presentation.
The Ethics Committee of the University of Basel approved the 
initial study protocol and all patients provided written informed 
consent for the first trial including consent for the use of their 
data in secondary biomarker analyses and follow-up. The Pro-
HOSP trial was registered at http://controlled-trials.com (identifier 
ISRCTN95122877).
Analysis of blood biomarker
Blood samples from all patients were collected upon ED admission. 
They were prepared to plasma and stored frozen at – 80 °C for later 
measurement of different blood markers.
The initial cohort consisted of 925 CAP patients. Baseline 
TRP, 5-HT, and KYN levels were measured in the plasma samples 
of 279 randomly selected subjects with available plasma samples. 
Therefore LC-MS/MS analysis was performed using an Ultimate 
3000 UHPLC (Thermo Fisher, San Jose, USA) system coupled to an 
ABSciex 5500 quadrupole mass spectrometer (ABSciex, Darmstadt, 
Germany) and AbsoluteIDQ p180  Kit (BIOCRATES Life Sciences 
AG, Innsbruck, Austria) as described in previous studies [16–18]. 
Briefly, a targeted profiling scheme is used to screen quantitatively 
for known small molecule metabolites using multiple reaction 
monitoring, neutral loss, and precursor ion scans. Quantification 
of the metabolites of the biological sample is achieved by reference 
to appropriate internal standards. Concentrations of all analyzed 
metabolites are reported in μmol/L [18]. Eleven measurements with 
a value of 0 μmol/L were excluded from our analysis because they 
were considered to be erroneous measurements. Based on the litera-
ture, normal range of TRP is at least 20 μmol/L or more [19]. Finally, 
we had a total number of 268 TRP, 250 KYN, and 213 5-HT measure-
ments for statistical analysis.
In infection, a decrease of TRP and an increase of KYN at the 
same time was previously found [20, 21]. Thus, the ratio of KYN/
TRP was proposed to be a sensitive indicator of IDO activity and is 
widely used in current research [22]. The same principle was done for 
 estimation of TPH.
Brought to you by | Universitaetsbibliothek Basel
Authenticated
Download Date | 10/9/17 4:17 PM
1062      Meier et al.: Tryptophan/serotonin pathway in pneumonia
Main outcome measurements
The primary endpoint was adverse outcome including 30-days all-
cause mortality or ICU admission. As secondary endpoints, mor-
tality at 30 days and 6-year mortality were defined. Survival status 
has been confirmed by structured phone interviews through trained 
medical students at day 30, 180 and 540 and at 6 years [15, 23]. The 
 pneumonia severity index (PSI) and quick sepsis-related organ failure 
assessment: altered mental status, fast respiratory rate ( ≥  22 breaths 
per min), low blood pressure (systolic blood pressure  ≤  100 mmHg) 
(qSOFA) were used as first clinical assessment scores. PSI is com-
posited by sex, past medical history, clinical, laboratory and radio-
logical findings [24]. Altered mental status, fast respiratory rate 
( ≥  22 breaths per min) and low blood pressure (systolic blood pres-
sure  ≤  100 mmHg) are used for qSOFA [25].
Statistical analysis
All statistical analysis were performed using STATA 12.1 (Stata Corp, 
College Station, TX, USA) and p < 0.05 (two-tailed) was considered to 
indicate statistical significance. Unless stated otherwise, categorical 
variables are expressed as percentages (numbers) and continuous 
variables as medians [interquartile range (IQR)]. The distribution of 
the biomarkers TRP, 5-HT, and KYN were skewed. After logarithmic 
transformation with a base of 10, the distribution of the biomarker 
data approximated a normal distribution. First, we calculated Spear-
man rank correlation to investigate effects of the metabolites of the 
TRP/5-HT pathway and inflammation [assessed by C-reactive pro-
tein (CRP)], infection (assessed by PCT), sepsis severity (assessed by 
qSOFA) and CAP severity (assessed by PSI). Next, we used univariate 
and multivariate logistic regression models to examine the associa-
tion of the metabolites and clinical outcomes, namely adverse out-
come defined as death and/or ICU admission, as well as death, both 
within 30 days of follow-up. The multivariate models were adjusted 
for age, gender, and comorbidities. Also, univariate and multivariate 
Cox regression models were used to investigate associations between 
metabolites levels at baseline and all-cause mortality over 6 years. 
The area under curve (AUC) with 95% CI (confidence interval) is 
presented to illustrate discrimination and predictive power. Kaplan-
Meier curves were used to represent mortality based on quartiles of 
the biomarkers (highest vs. lower three, except TRP lowest vs. higher 
three).
Results
Patient characteristics
Baseline characteristics of patients stratified by adverse 
outcome are presented in Table 1. In general, patients 
with an adverse outcome were older and had a trend for 
a higher body mass index. There was a high burden of 
comorbidities with chronic kidney disease being more 
frequent in patients with an adverse outcome. Also, 
patients with an adverse clinical outcome had higher PSI 
and qSOFA-scores.
When looking at different metabolites of the TRP/5-HT 
pathway, we found a negative correlation of IDO and TRP 
(Spearman rank: r2 = − 0.34, p < 0.001), as well as a posi-
tive correlation of IDO and KYN (Spearman rank: r2 = 0.69, 
p < 0.001) suggesting that higher IDO activity correlates 
with the catabolism of TRP to KYN.
Association of the tryptophan/serotonin 
pathway in inflammation and infection
In a first step, we investigated the association of the 
metabolites of the TRP/5-HT pathway with inflammation 
(assessed by CRP), infection (assessed by PCT), sepsis 
severity (assessed by qSOFA) and CAP severity (assessed 
by PSI). We found positive correlations of IDO with all of 
the markers above, particularly regarding PCT (Spearman 
rank: r2 = 0.34, p < 0.001) and PSI (Spearman rank: r2 = 0.39, 
p < 0.001) (see Table 2). Also, TRP was negatively corre-
lated with CRP (Spearman rank: r2 = − 0.24, p < 0.001) and 
PCT (Spearman rank: r2 = − 0.24, p < 0.001). KYN showed a 
positive association with qSOFA (Spearman rank: r2 = 0.14, 
p < 0.05) and PSI (Spearman rank: r2 = 0.34, p < 0.001).
Association of the tryptophan/serotonin 
pathway and adverse outcome
Next, we investigated the metabolites of the TRP/5-HT 
pathway with clinical outcomes. As illustrated in Figure 2, 
TRP was lower (median 41.2 μmol/L vs. 52.2 μmol/L, 
p = 0.041) and the ratio of IDO was increased (median 101.2 
vs. 67, p = 0.002) in patients with, as compared to those 
without an adverse outcome. This resulted in a trend of 
higher levels of KYN (median 4.3 μmol/L vs. 3.1 μmol/L, 
p = 0.088). There were no significant differences in 5-HT 
concentrations.
These results were also confirmed in Kaplan-Meier 
curves based on the highest quartile compared to the 
three lower quartiles to illustrate the association of the 
biomarkers with an adverse clinical outcome at 30  days 
(Figure 3). Because of the inverse association of TRP, we 
compared the lowest quartile with the three higher quar-
tiles for TRP plasma levels. The strongest effect was seen 
for TRP (p log rank = 0.005) and IDO (p log rank = 0.011). 
No effect was found for 5-HT.
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Table 1: Baseline characteristics of the study population by 1° outcome.
Characteristics
 
  No adverse outcome
n = 240
  Adverse outcome
n = 28
  p-Value
Demographic characteristics      
 Age median, years   71 (57, 82)   76 (66.5, 82.5)   0.120
 Male   144 (60.0%)   17 (60.7%)   0.940
 BMI   24.7 (22.0, 27.7)   26.6 (24.4, 29.5)   0.071
Comorbidities      
 Coronary artery disease   43 (17.9%)   8 (28.6%)   0.170
 Congestive heart failure   31 (12.9%)   4 (14.3%)   0.840
 Chronic kidney disease   46 (19.2%)   15 (53.6%)   < 0.001
 Diabetes mellitus   35 (14.6%)   5 (17.9%)   0.650
 Neoplastic disease   26 (10.8%)   5 (17.9%)   0.270
 Pneumopathy   58 (24.2%)   11 (39.3%)   0.083
Initial clinical findings      
 Pulse rate per minute   94 (82, 106)   97 (79, 114)   0.910
 Temperature, °C   38 (37.3, 39)   37.4 (36.7, 38.4)   0.022
 Systolic BP, mmHg   131 (120, 146.5)   125.5 (103.5, 139.5)   0.081
Initial clinical risk assesment      
 PSI      
  Class 1–2   67 (27.9%)   3 (10.7%)   0.001
  Class 3   55 (22.9%)   1 (3.6%)  
  Class 4–5   118 (49.2%)   24 (85.7%)  
 CURB-65      
  0–1 point   114 (47.5%)   5 (17.9%)   < 0.001
  2–3 points   120 (50.0%)   16 (57.1%)  
  4–5 points   6 (2.5%)   7 (25.0%)  
 qSOFA      
  0 point   128 (53.3%)   5 (17.9%)   < 0.001
  1 point   99 (41.2%)   16 (57.1%)  
  2–4 points   13 (5.4%)   7 (25.0%)  
Inflammatory markers      
 CRP, mg/L   127.5 (61.2, 236.5)   208.0 (90.5, 360.0)   0.022
 PCT, μg/L   0.38 (0.14, 2.88)   0.65 (0.21, 6.69)   0.089
 Creatinine, μmol/L   85 (69, 108)   117 (73, 179)   0.007
 Art. pH   7.45 (7.43, 7.49)   7.44 (7.38, 7.47)   0.029
Tryptophan/serotonin metabolism      
 Tryptophan, μmol/L   52.2 (40.3, 75.3)   41.2 (31.9, 66.4)   0.041
 Serotonin, μmol/L   0.2 (0.1, 0.3)   0.2 (0.1, 0.2)   0.940
 Kynurenine, μmol/L   3.1 (1.7, 5.6)   4.3 (1.7, 9.2)   0.230
 Tryptophan hydroxylase ratio   3.5 (2.2, 5.7)   4.1 (2.6, 8.4)   0.088
 Indoleamine 2,3-dioxygenase ratio  67.0 (44.5, 99.3)   101.2 (61.5, 186.3)   0.002
Data are presented as median (IQR) or no. (%). Bold p-values are statistically significant at p < 0.05. IQR, interquartile range (25th–75th 
 percentiles). Comorbidities were identified based on medical records of general practitioners, patient report, or both. Adverse outcome, 
30-days all-cause mortality or ICU admission. PSI, pneumonia severity index; CURB-65, pneumonia risk scoring system; qSOFA, quick 
sepsis-related organ failure assessment; CRP, C-reactive protein; PCT, procalcitonin; Art. pH, arterial pH.
Association between biomarkers and  
short- and long-term follow-up
Further, we also calculated univariate and multivari-
ate regression analysis to investigate the association of 
metabolites of the TRP/5-HT pathway and short-term 
outcome (death and adverse outcome within 30 days) as 
well as long-term outcome (mortality within 6 years). As 
presented in Table 3, TRP showed again an inverse associ-
ation with an adverse short-term outcome [adjusted odds 
ratio (OR) 0.11 (95% CI 0.02–0.7), p = 0.021], but was not 
associated with long-term outcome. KYN was associated 
with short- and long-term outcome in univariate analysis. 
After multivariate adjustment, these associations were 
no longer significant. Similarly, IDO showed a significant 
association in univariate analysis, but in multivariate 
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Table 2: Association of tryptophan/serotonin pathway with inflammation, infection, severity and sepsis score.
  CRP (inflammation)   PCT (infection)   PSI (severity)   qSOFA (sepsis)
Tryptophan   − 0.24 (p = 0.001)   − 0.24 (p = 0.001)   − 0.05 (p = 0.479)   − 0.02 (p = 0.778)
Serotonin   0.01 (p = 0.891)   − 0.10 (p = 0.138)   − 0.19 (p = 0.006)   − 0.02 (p = 0.753)
Kynurenine   − 0.08 (p = 0.251)   0.14 (p = 0.054)   0.34 (p < 0.001)   0.14 (p = 0.046)
Tryptophan 
hydroxylase
  0.14 (p = 0.046)   0.04 (p = 0.555)   − 0.17 (p = 0.015)   − 0.03 (p = 0.663)
Indoleamine 
2,3-dioxygenase
  0.14 (p = 0.042)   0.34 (p < 0.001)   0.39 (p < 0.001)   0.20 (p = 0.004)
Data for Spearman rank analysis are given as r2. Bold p-values are statistically significant at p < 0.05. CRP, C-reactive protein; 
PCT,  procalcitonin; PSI, pneumonia severity index; qSOFA, quick sepsis-related organ failure assessment.
10
8
6
4
2
0
10 200
No adverse outcome
Adverse outcome
Tryptophan hydroxylase
Kynurenine SerotoninTryptophan
Indoleamine 2,3-dioxygenase
p = 0.230 p = 0.002
p = 0.940p = 0.041p = 0.088
150
100
50
0
R
at
io
R
at
io
8
6
4
2
0
80
60
40
20
0
M
ed
ia
n 
(IQ
R)
, µ
m
o
l/L
M
ed
ia
n 
(IQ
R)
, µ
m
o
l/L
M
ed
ia
n 
(IQ
R)
, µ
m
o
l/L
0.3
0.2
0.1
0
Figure 2: Medians and their interquartile range (IQR) by 1° outcome.
Bold p-values are statistically significant at p < 0.05.
analysis only short-term outcome remained significant. 
No  associations were found for 5-HT.
Association of IDO with comorbidities
Finally, we conducted linear regression models to find 
out which comorbidities and parameters were associated 
with higher marker levels focusing on IDO, KYN, and TRP 
(Table 4). The strongest factor thereby was chronic kidney 
disease for IDO [adjusted correlation coefficient 0.27 
(95% CI 0.2–0.4), p < 0.001], TRP [0.12 (95% CI − 0.2–0), 
p = 0.004], and KYN [− 0.12 (95% CI − 0.2–0), p = 0.004], as 
well as age for TRP [0.02 (95% CI 0–0), p = 0.032] and KYN 
[0.03 (95% CI 0–0.1), p = 0.016].
Discussion
This study, examining the performance of metabolites 
of the TRP/5-HT pathway in a well-characterized cohort 
of CAP patients followed for over 6 years, revealed three 
key findings on hospital admission. First, we found a 
strong activation of IDO leading to a shift in metabolism 
from TRP to KYN dependent on infection, inflammation, 
and severity. No changes were found for circulating 
5-HT levels. Second, higher levels of IDO and KYN, as 
well as lower levels of TRP were associated with clinical 
patient outcomes. These associations, however, were 
partly explained by age and comorbidities as effects 
in multivariate models were less impressive. Third, 
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Table 3: Association of tryptophan/serotonin pathway by short-/long-term follow-up.
OR (95% CI), p-Value HR (95% CI), p-Value
Adverse outcome Death 30 days Death 6 years
Tryptophan
 Univariate OR 0.29 (0.09 to 1.2), p = 0.089 0.34 (0.05 to 2.5), p = 0.293 Univariate HR 1.17 (0.6 to 2.5), p = 0.684
 Multivariate ORa 0.11 (0.02 to 0.7), p = 0.021 0.16 (0.01 to 3.4), p = 0.240 Multivariate HRa 1.19 (0.5 to 3.0), p = 0.702
 AUC 0.38 (0.3 to 0.5) 0.44 (0.3 to 0.6) AUC 0.52 (0.4 to 0.6)
Serotonin    
 Univariate OR 1.00 (0.3 to 2.9), p = 0.993 0.95 (0.2 to 3.9), p = 0.941 Univariate HR 0.91 (0.6 to 1.4), p = 0.672
 Multivariate ORa 1.59 (0.4 to 6.3), p = 0.508 1.42 (0.2 to 8.4), p = 0.703 Multivariate HRa 1.20 ( 0.7 to 2.1), p = 0.515
 AUC 0.50 (0.4 to 0.6) 0.52 (0.3 to 0.7) AUC 0.46 (0.4 to 0.5)
Kynurenine      
 Univariate OR 4.54 (1.1 to 18.2), p = 0.033 10.1 (1.3 to 79.2), p = 0.028 Univariate HR 1.96 (1.0 to 3.7), p = 0.036
 Multivariate ORa 1.81 (0.3 to 9.6), p = 0.485 4.23 ( 0.2 to 93.2), p = 0.361 Multivariate HRa 0.86 (0.4 to 1.8), p = 0.676
 AUC 0.60 (0.5 to 0.7) 0.68 (0.5 to 0.8) AUC 0.58 (0.5 to 0.7)
Tryptophan hydroxylase      
 Univariate OR 2.20 (0.7 to 6.5), p = 0.154 1.50 (0.4 to 6.1), p = 0.571 Univariate HR 0.92 (0.6 to 1.4), p = 0.710
 Multivariate ORa 5.16 (1.1 to 24.0), p = 0.037 2.27 (0.4 to 14), p = 0.376 Multivariate HRa 1.13 (0.7 to 1.9), p = 0.653
 AUC 0.58 (0.4 to 0.7) 0.54 (0.3 to 0.7) AUC 0.45 (0.4 to 0.5)
Indoleamine 2,3-dioxygenase
 Univariate OR 11.2 (2.7 to 46.5), p = 0.001 12.37 (1.8 to 85.9), p = 0.011 Univariate HR 1.90 (1.0 to 3.5), p = 0.040
 Multivariate ORa 9.10 (1.4 to 59.5), p = 0.021 5.18 (0.3 to 105.6), p = 0.284 Multivariate HRa 0.77 ( 0.3 to 1.7), p = 0.526
 AUC 0.69 (0.6 to 0.8) 0.69 (0.5 to 0.9) AUC 0.60 (0.5 to 0.7)
Data for AUC, univariate and multivariate linear or Cox regression analyses are given as coefficient (95% CI). Bold p-values are statistically 
significant at p < 0.05. CI, confidence interval; OR, odds ratio; HR, hazard ratio. Adverse outcome, 30-days all-cause mortality or ICU admis-
sion. aMultivariate model: adjusted for patient age, gender and comorbidities (coronary artery disease, congestive heart failure, chronic 
kidney disease, diabetes mellitus, neoplastic disease, pneumopathy, body mass index).
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Figure 3: Kaplan-Meier curves by adverse outcome.
Bold p-values are statistically significant at p < 0.05. Adverse outcome, 30-days all-cause mortality or ICU admission.
the main parameters that influence the metabolites 
of the TRP/5-HT pathway were chronic kidney disease 
and age.
The present study showed a decrease of TRP in 
patients with CAP. This decrease correlated with higher 
disease severity as measured by higher levels of PCT 
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Table 4: Association with demographic characteristics and comorbidities in multivariate analyses.
OR (95% CI), p-Value
Tryptophan Kynurenine Indoleamine 2,3-dioxygenase
Patient characteristics    
 Age decades 0.02 (0 to 0), p = 0.032 0.03 (0 to 0.1), p = 0.016 0.02 (− 0.01 to 0.04), p = 0.180
 Male − 0.06 (− 0.1 to 0), p = 0.080 − 0.06 (− 0.1 to 0), p = 0.190 0.03 (− 0.1 to 0.1), p = 0.535
Comorbidities      
 Coronary artery disease − 0.05 (− 0.1 to 0), p = 0.263 − 0.03 (− 0.1 to 0.1), p = 0.563 0.004 (− 0.1 to 0.1), p = 0.936
 Congestive heart failure − 0.02 (− 0.1 to 0.1), p = 0.756 0.001 (− 0.1 to 0.1), p = 0.982 − 0.02 (− 0.1 to 0.1), p = 0.806
 Chronic kidney disease − 0.12 (− 0.2 to 0), p = 0.004 0.15 (0 to 0.3), p = 0.007 0.27 (0.2 to 0.4), p < 0.001
 Diabetes mellitus 0.01 (− 0.1 to 0.1), p = 0.807 0.01 (− 0.1 to 0.1), p = 0.916 0.01 (− 0.1 to 0.1), p = 0.861
 Pneumopathy 0.005 (− 0.1 to 0.1), p = 0.898 0.01 (− 0.1 to 0.1), p = 0.858 0.02 (− 0.1 to 0.1), p = 0.618
 Neoplastic disease − 0.09 (− 0.2 to 0), p = 0.083 − 0.01 (− 0.1 to 0.1), p = 0.884 0.07 (− 0.1 to 0.2), p = 0.258
 Body mass index 0.004 (0 to 0), p = 0.164 0.004 ( 0 to 0), p = 0.257 0.004 (− 0.01 to 0.01), p = 0.983
Data for multivariate linear regression analyses are given as coefficient (95% CI). Bold p-values are statistically significant at p < 0.05. 
CI, confidence interval.
and CRP, and higher risk scores (qSOFA and PSI). These 
results are in line with previous research [26–28]. The 
physiopathological mechanism of decreasing TRP during 
infection and inflammation is a matter of current discus-
sion [29]. It has been hypothesized early on that disease-
associated starvation and depletion by microbes may 
cause these effects. More recently, it has been proposed 
that the activation of the TRP/5-HT pathway is part of 
the host defense against infection and, thus, a benefi-
cial adaptation [30]. These considerations are important 
because IDO can be therapeutically influenced, which in 
turn may impact the treatment and recovery of the infec-
tion. Recently, a particular substance that inhibits IDO has 
been developed and tested in animal models, namely the 
IDO inhibitor 1-methyl-tryptophan [31]. In a mouse model, 
IDO inhibitors potentiated cancer chemotherapy because 
of an immune-modulating effect of IDO [32]. Also, a block-
ade of IDO showed a reduction in mortality from peritoni-
tis and sepsis in mice [27]. Despite these promising early 
results, clinical data is currently lacking demonstrating 
whether an IDO inhibitor could improve patient outcome 
in acute infection and sepsis. In this context, our clinical 
study showing a severity-dependent activation of IDO and 
a strong relationship to clinical outcome is relevant and 
may help to direct future interventional trials to answer 
the question, whether neutralization of the immunosup-
pressive effects could lead to a better infection control. 
Alternatively, an overwhelming reaction due to a suppres-
sion of the immune response in the human body would 
be possible.
Only a few studies have investigated the impact of 
the TRP/5-HT metabolism in patients with CAP. Similarly 
to our study, Suzuki et  al. [11] found an increase in IDO 
according to severity in a smaller cohort of CAP patients 
(129  subjects). Also, they studied short-term outcome 
and did multivariate regression analysis with laboratory 
parameters (e.g. CRP, blood urea nitrogen). The study, 
however, did not investigate long-term outcome, correla-
tion with comorbidities and 5-HT was not assessed. Our 
results thus validate these findings, but also expand the 
results regarding metabolites and clinical significance.
We did not find an increase in 5-HT in patients accord-
ing to severity and outcome. 5-HT is stored in platelets 
which are activated during infections resulting poten-
tially in endothelial hyperpermeability [33]. This secretion 
depends on the 5-HT transporter (SERT) [34]. From our 
results, it remains unclear why there was no evidence for 
increased 5-HT levels according to the severity of an infec-
tion. Possibly, inhibition by SERT-inhibitors could lower 
the peripheral levels of 5-HT [3]. Alternatively, pre-analyt-
ical issues and low metabolite stability could explain the 
lack of association.
Further, we investigated factors associated with the 
activation of the TRP/5-HT pathway. In multivariate analy-
sis, chronic kidney disease was found to be an impor-
tant predictor for IDO and KYN elevation. This is also in 
line with previous studies reporting decreased TRP and 
increased KYN and IDO levels in chronic kidney disease 
[35–37]. Renal excretion is known to be the main route 
of KYN elimination [38]. As mentioned above, IDO levels 
were still associated with adverse events after adjustment 
for chronic kidney disease, indicating that elevated KYN 
levels are not attributable to renal excretory impairment 
alone, but also to up-regulated metabolism (e.g. systemic 
inflammation). It is evident, that chronic Inflammation 
is a significant burden to patients with chronic kidney 
disease and is elevated by disease progression [39]. As 
suggested by previous clinical trials, elevated IDO and 
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KYN levels in chronic kidney diseases possibly indicate a 
chronic activation of the immune system [40].
As a second factor, age was found to be associ-
ated with TRP and KYN. These findings are in line with 
current research and are possibly explained by chronic 
 inflammation [41, 42].
The main strengths of this study include (i) the well-
characterized cohort of patients with CAP of different 
severities representative for patients usually treated in 
EDs and hospitals, (ii) the long and rigorous follow-up 
over a period of 6  years, and (iii) all-cause mortality as 
a primary outcome. Nevertheless, our study has limita-
tions. First, this study was conducted in several hospitals 
in Switzerland, and results may not be generalizable to 
other countries. Second, autopsies were not performed 
to verify the causes of death and therefore this study 
focused on all-cause mortality rather than acute infection 
caused events. Third, this was an observational study and 
as such just hypothesis generating. Finally, the ratios of 
IDO and TPH are estimated and not measured. In future 
evaluations, complete measurements of all involved 
metabolites should be performed including plasma free 
TRP, determinants of TRP binding (albumin and non-
esterified fatty acids), total TRP, TDO, IDO and levels of 
KYN metabolites [43].
Conclusions
In hospitalized CAP patients, higher IDO activity and 
lower TRP levels independently predicted disease sever-
ity and short-term adverse outcome. Whether therapeutic 
modulation of IDO has positive effects on outcome needs 
further investigation.
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